Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma Patients Who Have Previously Received Rituximab.

Trial Profile

Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma Patients Who Have Previously Received Rituximab.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Tositumomab
  • Indications B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Feb 2012 Actual patient number changed 40 to 43 as reported by ClinicalTrials.gov.
    • 19 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 May 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top